×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Altimmune to Participate at Two Upcoming Conferences
Yahoo Finance
GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company,...
3 days ago
Altimmune says weight loss drug minimized muscle loss in trial results, which may set it apart
CNBC
Altimmune on Wednesday said its experimental drug helped patients shed weight but also minimized the loss of muscle mass in a midstage trial, a...
1 month ago
Altimmune Obesity Drug Sheds Fat With Less Muscle Loss in Trial
Bloomberg
Altimmune Inc.'s experimental weight-loss drug minimized muscle decline in a mid-stage trial, a sign that it can address a problem obesity...
1 month ago
Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
Yahoo Finance
GAITHERSBURG, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company,...
2 days ago
Altimmune (NASDAQ:ALT) Rating Lowered to Neutral at Guggenheim
MarketBeat
Altimmune (NASDAQ:ALT - Get Free Report) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating in a research...
5 days ago
Altimmune shares pop as analysts see obesity-drug partnership potential
MarketWatch
Altimmune shares have jumped this week as analysts see potential for the company to find a partner for its promising experimental...
4 months ago
Altimmune call volume above normal and directionally bullish - TipRanks.com
Tipranks
Bullish option flow detected in Altimmune with 1463 calls trading, 1.2x expected, and implied vol increasing over 1 point to 110.32%.
3 days ago
Altimmune (ALT) to Report Q4 Earnings: What's in the Cards?
MSN
We expect investors to focus on Altimmune, Inc.'s ALT progress in the studies evaluating its lead product candidate, pemvidutide, when it reports...
6 days ago
Altimmune Joins Weight-Loss Race with Phase II Win, Stock Jumps on News
BioSpace
Patients treated with Altimmune's investigational GLP-1/glucagon dual receptor agonist saw up to 15.6% weight loss, and nearly a third of...
5 months ago
Altimmune (NASDAQ:ALT) Downgraded by Guggenheim to “Neutral”
Defense World
Guggenheim cut shares of Altimmune (NASDAQ:ALT – Free Report) from a buy rating to a neutral rating in a research report sent to investors...
4 days ago